Latest Insider Transactions at Evelo Biosciences, Inc. (EVLO)
This section provides a real-time view of insider transactions for Evelo Biosciences, Inc. (EVLO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Evelo Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Evelo Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,811
-7.52%
|
$0
$0.33 P/Share
|
|
Nov 08
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
172
-0.96%
|
$0
$0.33 P/Share
|
|
Nov 08
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,103
-15.45%
|
$0
$0.33 P/Share
|
|
Nov 08
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
3,163
-10.95%
|
$0
$0.33 P/Share
|
|
Nov 07
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+21.26%
|
-
|
|
Nov 07
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,172
+6.14%
|
-
|
|
Nov 07
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+24.45%
|
-
|
|
Nov 07
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
6,625
+18.65%
|
-
|
|
Nov 02
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,999
-18.54%
|
$0
$0.33 P/Share
|
|
Nov 02
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,854
-33.53%
|
$0
$0.33 P/Share
|
|
Nov 02
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
6,854
-23.53%
|
$0
$0.33 P/Share
|
|
Nov 01
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+36.69%
|
-
|
|
Nov 01
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+37.95%
|
-
|
|
Nov 01
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+30.03%
|
-
|
|
Sep 28
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
1,996
-10.64%
|
$5,988
$3.94 P/Share
|
|
Sep 27
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+44.44%
|
-
|
|
Aug 08
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,004
-18.1%
|
$18,036
$9.51 P/Share
|
|
Aug 08
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,434
-30.19%
|
$30,906
$9.51 P/Share
|
|
Aug 08
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
342
-8.35%
|
$3,078
$9.51 P/Share
|
|
Aug 08
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
3,128
-15.84%
|
$28,152
$9.51 P/Share
|
|
Aug 07
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+36.99%
|
-
|
|
Aug 07
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+36.36%
|
-
|
|
Aug 07
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,171
+22.23%
|
-
|
|
Aug 07
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
6,625
+25.12%
|
-
|
|
Jul 11
2023
|
Flagship Ventures Fund Iv General Partner LLC |
BUY
Open market or private purchase
|
Indirect |
5,411,255
+43.26%
|
$10,822,510
$2.31 P/Share
|
|
May 23
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
22,571
-7.92%
|
$0
$0.14 P/Share
|
|
May 08
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
3,537
-5.7%
|
$0
$0.13 P/Share
|
|
May 08
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
38,531
-29.64%
|
$0
$0.13 P/Share
|
|
May 08
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
68,014
-19.26%
|
$0
$0.13 P/Share
|
|
May 08
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
66,730
-40.63%
|
$0
$0.13 P/Share
|
|
May 07
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+44.18%
|
-
|
|
May 07
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
132,500
+27.28%
|
-
|
|
May 07
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,437
+27.42%
|
-
|
|
May 07
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+50.0%
|
-
|
|
Jan 31
2023
|
Mark D. Plinio Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+25.0%
|
$0
$0.88 P/Share
|
|
Jan 23
2023
|
Stephen J Carriere Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
151
-42.66%
|
$151
$1.06 P/Share
|
|
Jan 19
2023
|
Stephen J Carriere Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
354
+50.0%
|
-
|
|
Jul 29
2022
|
Mark D. Plinio Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+33.33%
|
$1,250
$1.79 P/Share
|
|
Jun 30
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,927
+2.59%
|
-
|
|
May 31
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,925
+2.73%
|
-
|
|
May 27
2022
|
Flagship Ventures Fund Iv General Partner LLC |
BUY
Open market or private purchase
|
Indirect |
27,397,259
+37.75%
|
$27,397,259
$1.46 P/Share
|
|
May 27
2022
|
David R Epstein Director |
BUY
Open market or private purchase
|
Direct |
17,123
+16.92%
|
$17,123
$1.46 P/Share
|
|
May 27
2022
|
Lord Ara Darzi Director |
BUY
Open market or private purchase
|
Direct |
342,465
+50.0%
|
$342,465
$1.46 P/Share
|
|
May 27
2022
|
Duncan Mc Hale Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
34,246
+50.0%
|
$34,246
$1.46 P/Share
|
|
May 02
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,926
+3.61%
|
-
|
|
Mar 31
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,926
+3.89%
|
-
|
|
Feb 28
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,926
+4.22%
|
-
|
|
Jan 31
2022
|
Mark D. Plinio Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+50.0%
|
$5,000
$4.0 P/Share
|
|
Jan 31
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,925
+4.61%
|
-
|
|
Dec 31
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,926
+5.08%
|
-
|